Induced pluripotent stem cells (iPSCs) represent a transformative platform for regenerative medicine and cell therapy, but clinical success depends on safe and reliable reprogramming methods. This study reports the first successful use of Touchlight’s doggybone DNA (dbDNA™) vectors to generate human iPSCs, offering a scalable, fully synthetic alternative to traditional plasmid-based episomal systems.

What this article covers:

• Use of dbDNA™ vectors for efficient iPSC reprogramming without bacterial DNA or p53 shRNA repression
• A direct comparison with OriP/EBNA1 episomal systems, highlighting reduced DNA damage, lower interferon response, and greater genomic stability
• Improvements in cell line stability and reduced spontaneous differentiation
• cGMP-compliant vector production suitable for therapeutic applications

With a reduced immunogenic profile and improved cell health outcomes, dbDNA™ offers a safer foundation for clinical-grade iPSC generation.

Download the full article to explore how dbDNA™ vectors advance the safety and stability of cell therapy development.